Jennifer Byrne among industry leaders featured by Lokavant in Applied Clinical Trials

New Legislation is Driving Diversity in Clinical Research

“[Currently] attempts at obtaining diversity in clinical trials have been half-hearted at best, often relegated to a secondary priority. Now, the Food and Drug Omnibus Reform Act (FDORA) will demand prioritization of representation in clinical trials, and companies that fall short will face repercussions.” – Rohit Nambisan, CEO and Co-Founder, Lokavant.

Hear more from Javara’s Jennifer Byrne, founder and CEO, and other pioneers across the space as they explore how technology can help companies adapt to these regulatory changes and realize more impactful DEI outcomes in the future. Read more with Applied Clinical Trials!